Single-nucleotide Polymorphism (SNP) for GlaucomaNCT01025024
Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients
An observational study of Single-nucleotide Polymorphism (SNP) for Glaucoma, run by Chungnam National University at 1 site in South Korea.
Trial summary
A single-nucleotide polymorphism (SNP) analysis of DNA obtained from peripheral blood of the glaucoma patients and the normal control will be performed to find genetic marker for primary open angle glaucoma. Read more about this study
- Who is it for?
- Ages 30 years and olderHealthy volunteers can take part
- Conditions the study is for
- Single-nucleotide Polymorphism (SNP) for Glaucoma
- What is being tested?
- SNP analysis of the DNA
- How many people
- 1,224 participants
- Where
- 1 siteSouth Korea
- Study dates
- Jan 2007to Nov 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: patients with open angle glaucoma who visited glaocoma clinic of departemtn of Ophtalmology, Chungnam National University Hospital, Daejeon, south Korea
Who may be able to join
- Clinical diagnosis of primary open angle glaucoma
Who cannot join
- Primary open angle glaucoma combined with congenital ocular disease
- Primary open angel glaucoma combined with other ocular disease
- Significant systemic disease other than systemic hypertension and diabetes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients Patients, A Single-nucleotide Polymorphism(SNP)Analysis for Primary Open Angle Glaucoma
A single-nucleotide polymorphism (SNP) analysis of DNA obtained from peripheral blood of the glaucoma patients and the normal control will be performed to find genetic marker for primary open angle glaucoma.
Read the detailed description
Unrelated Korean subjects who have primary open angle glaucoma were recruited in the current study. Genotyping for various SNP associated with POAG due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with primary open angle glaucoma and normal control subjects free of any eye diseases.
- Being tested
- SNP analysis of the DNA
- Keywords
- SNP, single-nucleotide polymorphism, glaucoma, primary open angle glaucoma
- Medical subject headings
- Glaucoma, Glaucoma, Open-Angle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SNP analysis of the DNAGenetic
SNP analysis of the DNA obtained from peripheral blood sample
| Study group | Role | What they receive |
|---|---|---|
| POAG group | Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect Receives: Genetic: SNP analysis of the DNA | |
| Normal control | Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease Receives: Genetic: SNP analysis of the DNA |
What is being measured
The primary outcome is the main question the study is designed to answer.
genotyping for the SNP associated with primary open angle glaucoma
Measured: one year
Secondary outcomes (1)
genotyping for rs7961953 and additional SNPs in TMTC2 from other linkage disequilibrium patterns
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2009 (estimated)
- Study startJan 2007
- Primary completionOct 2009
- Study completionNov 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Single-nucleotide Polymorphism (SNP) for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 1,224 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chungnam National University
- Sponsor type
- University, hospital or other
- Collaborators
- Korea Healthcare Technology R&D Project, Korea Advanced Institute of Science and Technology
- Investigators
- Chang-sik Kim, professor, Principal investigator, Department of Ophthalmology, Chungnam National University HospitalChangwon Kang, professor, Study chair, Korea Advanced Institute of Science and TechnologyKyunglan Kim, Study director, Department of Biological Sciences, Korea Advanced Institute of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01025024
- Sponsor's protocol ID
- CNUH81510-886
- Other IDs
- A080587
- Status last verified
- Dec 2009
- First submitted
- 2 Dec 2009
- Last updated
- 3 Dec 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients Patients, A Single-nucleotide Polymorphism(SNP)Analysis for Primary Open Angle Glaucoma
- ClinicalTrials.gov ID
- NCT01025024
- Acronym / sponsor ID
- CNUH81510-886
- Keywords
- SNP, single-nucleotide polymorphism, glaucoma, primary open angle glaucoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,224 participants (actual)
- Lead sponsor
- Chungnam National UniversityUniversity, hospital or other
- Collaborators
- Korea Healthcare Technology R&D Project, Korea Advanced Institute of Science and Technology
- Study start
- Jan 2007
- Primary completion
- Oct 2009 (actual)
- Study completion
- Nov 2009 (actual)
- First posted
- 3 Dec 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A single-nucleotide polymorphism (SNP) analysis of DNA obtained from peripheral blood of the glaucoma patients and the normal control will be performed to find genetic marker for primary open angle glaucoma.
Detailed description
Unrelated Korean subjects who have primary open angle glaucoma were recruited in the current study. Genotyping for various SNP associated with POAG due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with primary open angle glaucoma and normal control subjects free of any eye diseases.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| POAG group | – | Genetic: SNP analysis of the DNAElevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect |
| Normal control | – | Genetic: SNP analysis of the DNANormal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- patients with open angle glaucoma who visited glaocoma clinic of departemtn of Ophtalmology, Chungnam National University Hospital, Daejeon, south Korea
Key inclusion criteria (1 listed)
- Clinical diagnosis of primary open angle glaucoma
Key exclusion criteria (3 listed)
- Primary open angle glaucoma combined with congenital ocular disease
- Primary open angel glaucoma combined with other ocular disease
- Significant systemic disease other than systemic hypertension and diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SNP analysis of the DNASNP analysis of the DNA obtained from peripheral blood sample | Genetic | Normal control, POAG group |
Primary outcome
genotyping for the SNP associated with primary open angle glaucoma
Time frame: one year
1 secondary outcome
genotyping for rs7961953 and additional SNPs in TMTC2 from other linkage disequilibrium patterns
Time frame: one year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2009.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chang-sik Kim, professor principal investigator
Department of Ophthalmology, Chungnam National University Hospital
Changwon Kang, professor study chair
Korea Advanced Institute of Science and Technology
Kyunglan Kim study director
Department of Biological Sciences, Korea Advanced Institute of Science and Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Single-nucleotide Polymorphism (SNP) for Glaucoma, run by Chungnam National University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
genotyping for the SNP associated with primary open angle glaucoma (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2009.